Yuao Zhu
Research Subjects
Yuao Zhu has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
Devendra K. Rai
Anti-Infectives, Pfizer Research and Development, Pfizer Inc, Groton, CT, 06340, USA
3 shared publicationsHussin Rothan
Anti-Infectives, Pfizer Research and Development, Pfizer Inc, Pearl River, NY, 10965, USA
3 shared publicationsAnnaliesa S. Anderson
Pfizer Worldwide Research, Development & Medical, Pearl River, NY 10965, USA
2 shared publications- Irina Yurgelonis
Pfizer Global Research and Development, Pearl River, NY 10965, USA
2 shared publications - Jennifer Nicki
Discovery Sciences, Pfizer Research and Development, Pfizer Inc, Groton, CT, 06340, USA
2 shared publications - Li Hao
Pfizer Vaccines Research & Development, Pearl River, NY, USA
2 shared publications
Latest Publications
- Open Access
- 30 January 2026
- Published by Elsevier in Antiviral Research
- Vol. 248, 106352
Analysis of ibuzatrelvir's activity against SARS-CoV-2 circulating variants and in vitro resistance mutations
- 30 January 2026
- Published by Elsevier in Antiviral Research
- Vol. 248, 106352
Open AccessAnalysis of ibuzatrelvir's activity against SARS-CoV-2 circulating variants and in vitro resistance mutations
- Top Cited PapersOpen Access
- 30 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (35) , eado4288
Discovery of SARS-CoV-2 papain-like protease (PL pro ) inhibitors with efficacy in a murine infection model
Vaccines and first-generation antiviral therapeutics have provided important protection against COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there remains a need for additional therapeutic options that provide enhanced efficacy and protection against potential viral resistance. The SARS-CoV-2 papain-like protease (PL pro ) is one of the two essential cysteine proteases involved in viral replication. While inhibitors of the SARS-CoV-2 main protease have demonstrated clinical efficacy, known PL pro inhibitors have, to date, lacked the inhibitory potency and requisite pharmacokinetics to demonstrate that targeting PL pro translates to in vivo efficacy in a preclinical setting. Here, we report the machine learning–driven discovery of potent, selective, and orally available SARS-CoV-2 PL pro inhibitors, with lead compound PF-07957472 ( 4 ) providing robust efficacy in a mouse-adapted model of COVID-19 infection.
- 30 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (35) , eado4288
Top Cited PapersOpen AccessDiscovery of SARS-CoV-2 papain-like protease (PL pro ) inhibitors with efficacy in a murine infection model
Vaccines and first-generation antiviral therapeutics have provided important protection against COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there remains a need for additional therapeutic options that provide enhanced efficacy and protection against potential viral resistance. The SARS-CoV-2 papain-like protease (PL pro ) is one of the two essential cysteine proteases involved in viral replication. While inhibitors of the SARS-CoV-2 main protease have demonstrated clinical efficacy, known PL pro inhibitors have, to date, lacked the inhibitory potency and requisite pharmacokinetics to demonstrate that targeting PL pro translates to in vivo efficacy in a preclinical setting. Here, we report the machine learning–driven discovery of potent, selective, and orally available SARS-CoV-2 PL pro inhibitors, with lead compound PF-07957472 ( 4 ) providing robust efficacy in a mouse-adapted model of COVID-19 infection.
- Open Access
- 26 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (30)
In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance
To facilitate the detection and management of potential clinical antiviral resistance, in vitro selection of drug-resistant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) against the virus M pro inhibitor nirmatrelvir (Paxlovid active component) was conducted. Six M pro mutation patterns containing T304I alone or in combination with T21I, L50F, T135I, S144A, or A173V emerged, with A173V+T304I and T21I+S144A+T304I mutations showing >20-fold resistance each. Biochemical analyses indicated inhibition constant shifts aligned to antiviral results, with S144A and A173V each markedly reducing nirmatrelvir inhibition and M pro activity. SARS-CoV-2 surveillance revealed that in vitro resistance–associated mutations from our studies and those reported in the literature were rarely detected in the Global Initiative on Sharing All Influenza Data database. In the Paxlovid Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients trial, E166V was the only emergent resistance mutation, observed in three Paxlovid-treated patients, none of whom experienced COVID-19–related hospitalization or death.
- 26 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (30)
Open AccessIn vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance
To facilitate the detection and management of potential clinical antiviral resistance, in vitro selection of drug-resistant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) against the virus M pro inhibitor nirmatrelvir (Paxlovid active component) was conducted. Six M pro mutation patterns containing T304I alone or in combination with T21I, L50F, T135I, S144A, or A173V emerged, with A173V+T304I and T21I+S144A+T304I mutations showing >20-fold resistance each. Biochemical analyses indicated inhibition constant shifts aligned to antiviral results, with S144A and A173V each markedly reducing nirmatrelvir inhibition and M pro activity. SARS-CoV-2 surveillance revealed that in vitro resistance–associated mutations from our studies and those reported in the literature were rarely detected in the Global Initiative on Sharing All Influenza Data database. In the Paxlovid Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients trial, E166V was the only emergent resistance mutation, observed in three Paxlovid-treated patients, none of whom experienced COVID-19–related hospitalization or death.
- Open Access
- 5 October 2022
- Published by Elsevier in Antiviral Research
- Vol. 208, 105429
Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study
- 5 October 2022
- Published by Elsevier in Antiviral Research
- Vol. 208, 105429
Open AccessGeneration of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study